GLP-1 Agonists Linked to Increased Muscle Atrophy Risk in Large Study

Glucagon-like Peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide and liraglutide, are highly effective treatments for type 2 diabetes and obesity, primarily by promoting weight loss and improving glycemic control. While their benefits are well-established, there's an emerging concern that a portion of the weight lost might include valuable lean muscle mass. This study addresses the need for a large-scale, real-world assessment of the association between GLP-1 RA use and muscle atrophy.

The study revealed a statistically significant association between GLP-1 receptor agonist use and an increased risk of muscle atrophy. Patients on GLP-1 RAs had a 1.43-fold higher incidence of diagnosed muscle atrophy compared to the control group (HR 1.43, 95% CI 1.38-1.49, p<0.0001). This translated to an absolute risk of 15.2% among GLP-1 RA users developing atrophy over 3 years, versus 10.6% in the matched control cohort. The risk was consistent across different GLP-1 RA agents and patient subgroups. The most significant finding was a 43% increased incidence of diagnosed muscle atrophy in patients receiving GLP-1 receptor agonists over a 3-year follow-up period compared to matched controls (HR 1.43, 95% CI 1.38-1.49, p<0.0001). Notably, patients experiencing >10% total body weight loss on GLP-1 RAs showed an even higher 2.1-fold increased risk of atrophy compared to those with less weight loss.